Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Immunotherapy and Immune Responses, and Monoclonal and Polyclonal Antibodies Research.
Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma